Registration Options

Activity Date: 04/28/2020

Registration is not configured for this course.

Session Time and Location

The live session is complete.

Target Audience

This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Mood, anxiety, and substance-use disorders are among the most prevalent mental illnesses in the population. While several pharmacological treatments are available, not all patients are successfully treated with these agents. Recent studies suggest that psychedelic agents including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxy-methamphetamine (MDMA) may be helpful adjunctive treatments for depression, anxiety, and substance use disorders. After this session, participants will be able to summarize the available literature and ongoing research in the use of psychedelic agents and individuals living with mental illness.

Course Requirements

To receive ACPE credit for the live session at the Annual Meeting, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Attend and participate in the entire session and reflect upon its teachings.
  • Complete the evaluation at the end of the activity.
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information

Frederick S. Barrett, PhD

View biographical information

Learning Objectives

  1. Describe the neurophysiology of psychedelic-induced states of mind and the relation between these brain states and healing mechanisms for anxiety, depression, and existential suffering.
  2. Summarize the available literature available on the use of psychedelics including psilocybin, lysergic acid diethylamide (LSD), ketamine, and 3,4-methylenedioxy-methamphetamine (MDMA).
  3. Evaluate the current place in therapy for use of psychedelic agents in individuals with mental illness.
  4. Discuss future directions of psychedelic research in psychiatry.

Continuing Education Credit and Disclosures

Activity Date: 04/28/2020
ACPE Contact Hours: 1
ACPE Number: 0284-0000-20-021-L01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.